Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.

Zhou Y, Wu Y, Qin Y, Liu L, Wan J, Zou L, Zhang Q, Zhu J, Mi M.

PLoS One. 2016 Jul 8;11(7):e0159191. doi: 10.1371/journal.pone.0159191.

2.

Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases.

Cheng P, Zhang F, Yu L, Lin X, He L, Li X, Lu X, Yan X, Tan Y, Zhang C.

J Diabetes Res. 2016;2016:1540267. doi: 10.1155/2016/1540267. Review.

3.

Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state.

Guan D, Zhao L, Chen D, Yu B, Yu J.

J Transl Med. 2016 Mar 1;14:63. doi: 10.1186/s12967-016-0821-0. Review.

4.

Reciprocal Effects on Neurocognitive and Metabolic Phenotypes in Mouse Models of 16p11.2 Deletion and Duplication Syndromes.

Arbogast T, Ouagazzal AM, Chevalier C, Kopanitsa M, Afinowi N, Migliavacca E, Cowling BS, Birling MC, Champy MF, Reymond A, Herault Y.

PLoS Genet. 2016 Feb 12;12(2):e1005709. doi: 10.1371/journal.pgen.1005709.

5.

Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD.

Inagaki T.

Front Endocrinol (Lausanne). 2015 Sep 23;6:147. doi: 10.3389/fendo.2015.00147. Review.

6.

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21.

Domouzoglou EM, Naka KK, Vlahos AP, Papafaklis MI, Michalis LK, Tsatsoulis A, Maratos-Flier E.

Am J Physiol Heart Circ Physiol. 2015 Sep 15;309(6):H1029-38. doi: 10.1152/ajpheart.00527.2015. Review.

7.

Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity.

Mayoral R, Osborn O, McNelis J, Johnson AM, Oh DY, Izquierdo CL, Chung H, Li P, Traves PG, Bandyopadhyay G, Pessentheiner AR, Ofrecio JM, Cook JR, Qiang L, Accili D, Olefsky JM.

Mol Metab. 2015 Mar 5;4(5):378-91. doi: 10.1016/j.molmet.2015.02.007.

8.

Maternal High-Fat Feeding Increases Placental Lipoprotein Lipase Activity by Reducing SIRT1 Expression in Mice.

Qiao L, Guo Z, Bosco C, Guidotti S, Wang Y, Wang M, Parast M, Schaack J, Hay WW Jr, Moore TR, Shao J.

Diabetes. 2015 Sep;64(9):3111-20. doi: 10.2337/db14-1627.

9.

Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and β-klotho expression decrease with fasting in northern elephant seals.

Suzuki M, Lee AY, Vázquez-Medina JP, Viscarra JA, Crocker DE, Ortiz RM.

Gen Comp Endocrinol. 2015 May 15;216:86-9. doi: 10.1016/j.ygcen.2015.03.009.

10.

Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance.

Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F.

Front Physiol. 2015 Jan 30;6:4. doi: 10.3389/fphys.2015.00004. Review.

11.

The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway.

Vernia S, Cavanagh-Kyros J, Garcia-Haro L, Sabio G, Barrett T, Jung DY, Kim JK, Xu J, Shulha HP, Garber M, Gao G, Davis RJ.

Cell Metab. 2014 Sep 2;20(3):512-25. doi: 10.1016/j.cmet.2014.06.010.

12.

Transcriptional regulation of fibroblast growth factor 21 expression.

Bae KH, Kim JG, Park KG.

Endocrinol Metab (Seoul). 2014 Jun;29(2):105-11. doi: 10.3803/EnM.2014.29.2.105. Review.

13.

ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress.

Wan XS, Lu XH, Xiao YC, Lin Y, Zhu H, Ding T, Yang Y, Huang Y, Zhang Y, Liu YL, Xu ZM, Xiao J, Li XK.

Biomed Res Int. 2014;2014:807874. doi: 10.1155/2014/807874.

14.

Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR).

Cheng X, Vispute SG, Liu J, Cheng C, Kharitonenkov A, Klaassen CD.

Toxicol Appl Pharmacol. 2014 Jul 1;278(1):65-71. doi: 10.1016/j.taap.2014.04.013.

15.

Inventing new medicines: The FGF21 story.

Kharitonenkov A, Adams AC.

Mol Metab. 2013 Dec 27;3(3):221-9. doi: 10.1016/j.molmet.2013.12.003. Review.

16.

Regulators of human white adipose browning: evidence for sympathetic control and sexual dimorphic responses to sprint interval training.

Scalzo RL, Peltonen GL, Giordano GR, Binns SE, Klochak AL, Paris HL, Schweder MM, Szallar SE, Wood LM, Larson DG, Luckasen GJ, Hickey MS, Bell C.

PLoS One. 2014 Mar 6;9(6):e90696. doi: 10.1371/journal.pone.0090696.

17.

Calorie restriction and sirtuins revisited.

Guarente L.

Genes Dev. 2013 Oct 1;27(19):2072-85. doi: 10.1101/gad.227439.113. Review.

18.

Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich Ataxia).

Salehi MH, Kamalidehghan B, Houshmand M, Aryani O, Sadeghizadeh M, Mossalaeie MM.

Mol Biol Rep. 2013 Nov;40(11):6495-9.

19.

Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Adams AC, Coskun T, Cheng CC, O Farrell LS, Dubois SL, Kharitonenkov A.

Mol Metab. 2013 May 29;2(3):205-14. doi: 10.1016/j.molmet.2013.05.005.

20.

Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21.

Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, Guo H, Li Z, Li W, Hu W, Jiang G, Paweletz CP, Hendrickson RC, Thompson JR, Mu J, Berger JP, Mehmet H.

PLoS One. 2013 Sep 6;8(9):e73011. doi: 10.1371/journal.pone.0073011.

Items per page

Supplemental Content

Support Center